Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
AGLE

AGLE - Aeglea BioTherapeutics Inc Stock Price, Fair Value and News

27.60USD-0.08 (-0.29%)Market Closed

Market Summary

AGLE
USD27.60-0.08
Market Closed
-0.29%

AGLE Stock Price

View Fullscreen

AGLE RSI Chart

AGLE Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-3.04

Price/Sales (Trailing)

216.37

EV/EBITDA

-2.42

Price/Free Cashflow

-10

AGLE Price/Sales (Trailing)

AGLE Profitability

EBT Margin

-7112.95%

Return on Equity

-239.2%

Return on Assets

-74.7%

Free Cashflow Yield

-10%

AGLE Fundamentals

AGLE Revenue

Revenue (TTM)

5.1M

Rev. Growth (Yr)

955.24%

Rev. Growth (Qtr)

-100%

AGLE Earnings

Earnings (TTM)

-364.2M

Earnings Growth (Yr)

-138.07%

Earnings Growth (Qtr)

30.58%

Breaking Down AGLE Revenue

Last 7 days

14.0%

Last 30 days

51.4%

Last 90 days

158.0%

Trailing 12 Months

122.8%

How does AGLE drawdown profile look like?

AGLE Financial Health

Current Ratio

11.38

AGLE Investor Care

Shares Dilution (1Y)

1440.00%

Diluted EPS (TTM)

-46.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20245.1M000
20231.4M1.4M1.3M1.1M
202220.1M7.0M5.8M2.3M
20215.5M9.9M14.3M18.7M
20201.5M1.7M1.1M0
201903.0M1.2M0
20185.7M6.6M5.4M3.9M
20174.8M4.9M5.0M5.2M
20166.9M4.9M5.0M4.6M
20150006.1M

Tracking the Latest Insider Buys and Sells of Aeglea BioTherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 24, 2023
fairmount funds management llc
acquired
-
-
3,435,480
-
Nov 24, 2023
turtle cameron
acquired
-
-
723,440
chief executive officer
Aug 25, 2022
souza marcio
bought
50,472
0.5608
90,000
-
Jun 08, 2022
hanley jr. michael conick
bought
20,022
0.71
28,200
chief commercial officer
Mar 16, 2022
quinn anthony g.
bought
187,705
2.344
80,079
president & ceo
Mar 15, 2022
quinn anthony g.
bought
78,942
1.8611
42,417
president & ceo
Mar 14, 2022
quinn anthony g.
bought
130,221
1.93
67,472
president & ceo
Mar 11, 2022
quinn anthony g.
bought
71,779
2.064
34,777
president & ceo
Mar 11, 2022
alspaugh jonathan
bought
156,000
2.08
75,000
chief financial officer
Dec 13, 2021
shanafelt armen
bought
53,600
3.65
14,685
-

1–10 of 39

Which funds bought or sold AGLE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
new
-
17,675,400
17,675,400
0.08%
May 20, 2024
Virtu Financial LLC
new
-
615,000
615,000
0.05%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
new
-
675,268
675,268
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
273,475
273,475
-%
May 15, 2024
Boxer Capital, LLC
unchanged
-
4,102,500
9,482,500
0.47%
May 15, 2024
Walleye Capital LLC
new
-
4,228,360
4,228,360
0.01%
May 15, 2024
Yu Fan
new
-
16,449,800
16,449,800
22.68%
May 15, 2024
Schonfeld Strategic Advisors LLC
new
-
1,346,520
1,346,520
0.01%
May 15, 2024
Squarepoint Ops LLC
new
-
309,547
309,547
-%
May 15, 2024
Avoro Capital Advisors LLC
unchanged
-
30,180,300
69,758,500
0.81%

1–10 of 50

Are Funds Buying or Selling AGLE?

Are funds buying AGLE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGLE
No. of Funds

Unveiling Aeglea BioTherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 10, 2024
fmr llc
-
0
SC 13G/A
Apr 25, 2024
fairmount funds management llc
9.99%
4,024,541
SC 13D/A
Apr 23, 2024
avoro capital advisors llc
5.1%
1,839,138
SC 13G/A
Mar 11, 2024
fmr llc
-
0
SC 13G/A
Feb 14, 2024
logos global management lp
0.4%
150,000
SC 13G/A
Feb 14, 2024
perceptive advisors llc
7.2%
2,606,679
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
0.0%
0
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
0%
0
SC 13G/A
Feb 14, 2024
rtw investments, lp
6.2%
2,232,760
SC 13G
Feb 14, 2024
ecor1 capital, llc
2.5%
887,076
SC 13G/A

Recent SEC filings of Aeglea BioTherapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 10, 2024
SC 13G/A
Major Ownership Report
May 30, 2024
8-K
Current Report
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
3
Insider Trading
May 15, 2024
424B3
Prospectus Filed
May 15, 2024
8-K
Current Report

Peers (Alternatives to Aeglea BioTherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Aeglea BioTherapeutics Inc News

Latest updates
Yahoo Movies UK30 May 202408:20 am

Aeglea BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q32020Q22020Q12019Q32019Q22018Q42018Q32018Q2
Revenue-4,432,000--688,000420,000168,000174,000625,0001,362,0003,644,0001,399,00013,696,0006,892,00088,000161,000300,000585,000619,00012,000-2,378,000
Operating Expenses4.1%47,774,00045,914,00018,337,000159,934,00019,004,00019,330,00018,929,00023,048,00025,803,00024,086,00021,692,00020,401,00018,209,00018,123,00021,560,00019,022,00022,146,00018,622,00015,305,00012,243,00012,048,000
  S&GA Expenses-8.7%12,846,00014,072,0008,584,00012,062,0005,228,0005,079,0006,952,0007,675,0008,825,0007,304,0006,839,0006,822,0006,354,0005,672,0004,691,0004,460,0004,307,0003,816,0003,507,0003,314,0002,926,000
  R&D Expenses-----13,776,00014,251,00011,977,00015,373,00016,978,00016,782,00014,853,00013,579,00011,855,00012,451,00016,869,00014,562,00017,839,00014,806,00011,798,0008,929,0009,122,000
EBITDA Margin76.7%-71.06-305-278-220-65.61-35.38-14.47-12.21-3.50-3.66-4.62-6.80---------
Income Taxes-32,000-3,0007,000-36,00051,000-209,0009,000-23,00026,00092,000---------
Earnings Before Taxes30.6%-43,825,000-63,180,000-40,104,000-217,074,000-18,458,000-18,771,000-18,443,000-22,314,000-24,436,000-20,423,000-20,281,000-6,738,000--18,033,000-21,418,000------
EBT Margin76.7%-71.13-305-279-222-66.94-36.05-14.75-12.44-3.58-3.74-4.73-6.93---------
Net Income30.6%-43,857,000-63,180,000-40,107,000-217,081,000-18,422,000-18,822,000-18,234,000-22,323,000-24,436,000-20,446,000-20,307,000-6,830,000-18,218,000-18,033,000-21,418,000-18,728,000-21,573,000-18,019,000-14,898,000-11,917,000-9,414,000
Net Income Margin76.7%-71.14-305-279-221-66.78-35.99-14.72-12.45-3.58-3.51-4.75-6.62---------
Free Cashflow8.0%-28,542,000-31,036,000-34,597,000-16,643,000-17,634,000-18,140,000-15,069,000-20,673,000-26,300,000-19,268,000-17,093,0002,052,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets42.6%48834220724452.0071.0092.0010783.0011012914716416215617365.0083.00100117129
  Current Assets42.7%48734220624044.0062.0082.0097.0073.0099.0011813415115014416254.0075.0093.00110127
    Cash Equivalents20.5%22818991.003.0037.0036.0041.0037.0015.0017.0025.0035.0080.0092.0054.0066.0013.0019.0025.0025.0086.00
  Net PPE-----3.003.004.004.004.005.005.005.006.006.005.005.004.002.001.001.001.00
Liabilities11.8%82.0073.0066.0025419.0021.0024.0023.0022.0026.0027.0028.0040.0022.0019.0021.0022.0023.0020.0018.0012.00
  Current Liabilities33.9%43.0032.0045.0023213.0015.0018.0016.0016.0020.0020.0021.0032.0016.0014.0016.0017.0018.0015.0013.0012.00
Shareholder's Equity-17.3%152184--34.0050.0068.0084.0062.0084.0010211912414013615243.0060.0080.00100116
  Retained Earnings-5.7%-808-764-701-661-444-425-406-388-366-341-321-301-294-276-253-235-213-195-173-152-134
  Additional Paid-In Capital1.7%776763456454478476475473428426423420418416390387257255253252250
Shares Outstanding1.6%37.0036.004.003.004.003.003.003.003.003.003.003.00---------
Float----26.00---30.00---337---386---178-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations8.0%-28,542-31,036-34,597-16,643-17,634-18,140-15,068-20,673-26,263-19,268-17,0002,082-19,530-17,132-17,536-19,413-21,694-16,294-17,208-16,383-15,807
  Share Based Compensation-20.1%13,80017,2704,7851,9111,7091,4271,5662,0172,1012,0942,1072,0801,7571,6121,6961,6001,3481,1841,3661,2451,081
Cashflow From Investing-197.6%-104,963-35,272-97,6316,76017,75014,00016,49975025,7599,6635,777-47,3599,30028,6205,784-56,76114,75310,32616,012-42,01313,936
Cashflow From Financing5.2%172,165163,606-12,531209,99210.00-8.00-13042,80412.0080.001,143-19236224,679258129,293282676311-31965,055
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AGLE Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 0$ 198
Operating expenses:  
Research and development[1]34,92813,776
General and administrative12,8465,228
Total operating expenses47,77419,004
Loss from operations(47,774)(18,806)
Other income (expense):  
Interest income4,432420
Other expense(483)(72)
Total other income (expense)3,949348
Loss before income tax expense(43,825)(18,458)
Income tax (expense) benefit(32)36
Net loss$ (43,857)$ (18,422)
Net loss per share, basic (in dollars per share)$ (1.20)$ (4.89)
Net loss per share, diluted (in dollars per share)$ (1.20)$ (4.89)
Weighted-average common shares outstanding, basic (in shares)36,512,6623,770,506
Weighted-average common shares outstanding, diluted (in shares)36,512,6623,770,506
Development fee and royalty  
Revenue:  
Total revenue$ 0$ 198
[1]Includes $17.1 million in related party expenses for the three months ended March 31, 2024 and no related party expenses for the three months ended March 31, 2023.

AGLE Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS  
Cash and cash equivalents$ 227,552$ 188,893
Marketable securities257,089150,384
Prepaid expenses and other current assets2,6322,251
Total current assets487,273341,528
Restricted cash319322
Other non-current assets109
TOTAL ASSETS487,602341,859
CURRENT LIABILITIES  
Accounts payable3,106896
CVR liability2,5901,390
Accrued and other current liabilities21,59413,108
Related party accounts payable and other current liabilities15,52816,584
Total current liabilities42,81831,978
Non-current CVR liability39,11041,310
TOTAL LIABILITIES81,92873,288
Commitments and Contingencies (Note 6)
STOCKHOLDERS’ EQUITY  
Common stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 36,629,680 shares and 36,057,109 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively1010
Additional paid-in capital775,966763,191
Accumulated other comprehensive (loss) income(363)302
Accumulated deficit(808,271)(764,414)
TOTAL STOCKHOLDERS’ EQUITY152,269184,016
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY487,602341,859
Series B Non Voting Convertible Preferred Stock  
CURRENT LIABILITIES  
Series B non-voting convertible preferred stock, $0.0001 par value; $271,625 and $150,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; $271,625 and $150,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively253,40584,555
Series A Non Voting Convertible Preferred Stock  
STOCKHOLDERS’ EQUITY  
Series A non-voting convertible preferred stock & preferred stock shares authorized, issued, and outstanding, value184,927184,927
Preferred Stock, Excluding Series A Non Voting Convertible Preferred Stock  
STOCKHOLDERS’ EQUITY  
Series A non-voting convertible preferred stock & preferred stock shares authorized, issued, and outstanding, value$ 0$ 0
AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
 WEBSITEaeglea.com
 INDUSTRYBiotechnology
 EMPLOYEES14

Aeglea BioTherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aeglea BioTherapeutics Inc? What does AGLE stand for in stocks?

AGLE is the stock ticker symbol of Aeglea BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aeglea BioTherapeutics Inc (AGLE)?

As of Tue Apr 30 2024, market cap of Aeglea BioTherapeutics Inc is 1.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers. The fair value of Aeglea BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aeglea BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGLE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aeglea BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGLE is over valued or under valued. Whether Aeglea BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Aeglea BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGLE.

What is Aeglea BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, AGLE's PE ratio (Price to Earnings) is -3.04 and Price to Sales (PS) ratio is 216.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGLE PE ratio will change depending on the future growth rate expectations of investors.